Bli medlem
Bli medlem

Du är här


2cureX publishes interim report for the fourth quarter and full year of 2022

2cureX AB (“2cureX”) hereby publishes the interim report for the fourth quarter and full year of 2022. The interim report is available as an attached document as well as on the company’s website ( A short summary of the report follows below.

CEO Fernando Andreu comments:

“We finished a very successful 2022 and are proud to look back at a year where we met our goal of having IndiTreat present in 20 countries, with a total population of approximately 385M people. This - together with the expansion of our product portfolio - has considerably advanced our lead in the race for the Functional Drug Sensitivity Testing (f-DST) market.

The fourth quarter of 2022 was our strongest quarter to date, and in this quarter we enrolled as many as 9 additional hospitals to the IGNITE program compared to our revised goal of 5 hospitals. Once again we received reaffirmation that our IGNITE program is a good path to expose the benefits of IndiTreat to potential customers and we will continue our efforts on driving this forward.

Building on the positive developments of 2022 we have set ambitious goals for 2023, where we will focus our efforts and activities on penetrating the incipient European market as well as pushing forward on expanding the adoption of the f-DST technology.”

The financial development is in line with our plans and expectations, and with a cash position of SEK 45 MSEK at the end of 2022, our capital resources can support the current activities and growth plans.”

Full year of 2022 (2022-01-01 until 2022-12-31) – the group

Net turnover for the period was 90 KSEK (0 KSEK).
Other operating income was 3 279 KSEK (7 391 KSEK)
The result before tax was -29 770 KSEK (-22 479 KSEK)
The result per share* was -1.69 SEK (-1.15 SEK)
The solidity** was 90 % (94 %).
The cash and bank were 44 894 KSEK (72 942 KSEK).

*Earnings per share: Profit for the period divided by the average number of shares. Average number of shares in 2022: 17 580 961 shares. Total number of shares in 2cureX AB on December 31st, 2022: 17 602 916 shares.
**Equity ratio: Shareholder’s equity divided by total capital.

Significant events during the fourth quarter 2022


2cureX celebrates co-inventor of patents awarded Nobel Prize in Chemistry

Independent market survey shows great demand for 2cureX product portfolio


2cureX hosted a deep dive session of its operational and commercial strategy

2curex discloses status of 2022 plans, goals for 2023 and its estimates of potential market development in the coming years

2cureX publishes interim report for the third quarter 2022 and presents in live webcast


2curex announces reaching the 2022 geographic rollout goal of 20 countries

Significant events after the period


2curex announces final results regarding 2022 goals

2curex sends notice to attend the extraordinary general meeting for new board member

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
Telephone: +45 2279 5399

Kenneth Graabek Johansen, Chief Financial Officer
Telephone: +45 2349 0227

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit
Certified Adviser: Redeye AB, +46 8 121 576 90,

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-23 08:30 CET.


2curex Q4 Report UK 2022 6korrektur

Författare MFN